Amgen Inc (AMGN)
Amgen Inc. is a global biopharmaceutical company focused on developing and manufacturing innovative medicines in areas such as oncology, nephrology, and inflammation. Founded in 1980, Amgen is known for its work in biologic therapies and has a strong portfolio of blockbuster drugs aimed at improving patient lives.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 12, 2025 | $2.38 | 2025-08-22 | 2025-08-22 |
| June 6, 2025 | $2.38 | 2025-05-16 | 2025-05-16 |
| March 7, 2025 | $2.38 | 2025-02-14 | 2025-02-14 |
| December 9, 2024 | $2.25 | 2024-11-18 | 2024-11-18 |
| September 6, 2024 | $2.25 | 2024-08-16 | 2024-08-16 |
Dividends Summary
- Amgen Inc has issued 57 dividend payments over the past 14 years
- The most recent dividend was paid 8 days ago, on September 12, 2025
- The highest dividend payed out to investors during this period was $2.38 per share
- The average dividend paid during this period was $1.32 per share.
Company News
Phoenix Group's £22 billion move from Aberdeen Group creates a potential investment opportunity in healthcare-focused closed-end funds with high dividend yields, particularly Abrdn Healthcare Investors and Abrdn Healthcare Opportunities Fund.
Eli Lilly is emerging as a leader in the weight loss drug market, with blockbuster drugs Mounjaro and Zepbound generating significant revenue. The company is developing additional weight loss treatments, including an oral pill and a potentially more effective injectable drug, positioning itself strongly in a market expected to grow to $95 billion by decade's end.
Chinese biopharma firm Zai Lab experienced a significant stock decline after disappointing Phase 3 trial results for its gastric cancer drug bemarituzumab and underwhelming quarterly earnings, with weak sales of core products impacting investor confidence.
Kyowa Kirin and Amgen are collaborating to develop rocatinlimab, a potential T-cell rebalancing therapy for moderate-to-severe atopic dermatitis. The Phase 3 ROCKET-SHUTTLE trial results will be presented at the European Academy of Dermatology and Venerology Congress in Paris.
The article discusses the Invesco Large Cap Value ETF (PWV), which provides broad exposure to the large-cap value segment of the market. It highlights the fund's investment strategy, performance, and risk profile, as well as compares it to similar ETFs like Schwab U.S. Dividend Equity ETF (SCHD) and Vanguard Value ETF (VTV).
